8-K: Niagen Bioscience Reports Q2 2026 Results, Launches Pharma Program

Niagen Bioscience announced Q2 2026 results with $29.8M in net sales, launched a telehealth platform, and introduced a new therapeutic candidate for rare diseases.

Summary

• Niagen Bioscience reported second quarter 2026 net sales of $29.8 million, with $24.2 million from Tru Niagen.
• Direct-to-consumer sales on the company's website increased by 23% year-over-year.
• The company achieved a gross margin of 64.8%.
• Net income for the quarter was $1.0 million, or $0.01 per diluted share.
• Adjusted EBITDA was $3.0 million.
• Operating cash flow for the first six months of 2026 was $1.6 million, and the company ended the period with $66.7 million in cash and cash equivalents.
• Key strategic initiatives included the launch of the Niagen Plus telehealth platform and the introduction of NB4168, a therapeutic candidate for rare genetic diseases and aging-related disorders.
• NB4168 received Rare Pediatric Disease designation from the FDA and Orphan Medicinal Product designation from the EMA.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, highlighting strategic advancements and solid consumer sales, though tempered by increased operating expenses for future growth initiatives.

Positives

• Direct-to-consumer sales growth of 23% year-over-year indicates strong customer engagement.
• Gross margin remains strong at 64.8%, demonstrating pricing power and efficient cost of goods sold.
• Positive operating cash flow of $1.6 million year-to-date.
• Substantial cash reserves of $66.7 million provide financial flexibility for investments.
• Successful launch of the Niagen Plus telehealth platform and at-home injection kit.
• Introduction of NB4168, a promising therapeutic candidate with favorable regulatory designations (RPD and OMPD).
• Repurchased $2.8 million of common stock, indicating a commitment to shareholder value.
• LegitScript certification for Niagen Plus enables advertising of at-home injection kits.

Negatives

• Net sales decreased slightly to $29.8 million in Q2 2026 from $31.1 million in Q2 2025.
• Operating expenses increased to $18.6 million in Q2 2026 from $17.0 million in Q2 2025, driven by investments in strategic initiatives.
• Ingredient business expected to be lower than the prior year due to competitive market conditions for commercial partners.
• Niagen Plus growth and new skincare partnerships are not expected to be meaningful contributors until 2027.

Risks

• Continued competition from other providers and products, including other supplements such as NMN.
• Risks in product development and the ability to develop the pharmaceutical business.
• Inability to raise capital to fund continuing operations or new product development.
• Changes in government regulation or regulatory priorities.
• Economic and market instability, including inflationary conditions and adverse economic conditions.
• Reliance on a single or limited number of third-party suppliers.
• Unanticipated developments and risks related to securing adequate quantities of pharmaceutical-grade Niagen.
• Potential for clinical trial results to be unsuccessful or insufficient to meet regulatory standards.

Future Outlook

For the full year 2026, the Company expects its e-commerce business to grow 10% to 15% year-over-year, with the remainder of the consumer business performing in line with prior expectations. The ingredient business is projected to be lower than the prior year. Niagen Plus growth and new skincare partnerships are anticipated to become meaningful contributors starting in 2027. Operating expenses are expected to increase in 2026 due to strategic investments.

Management Comments

• "Our underlying consumer products business is the engine funding the rest of our value accretive initiatives and we are focused on investing across our multiple strategic growth opportunities, while maintaining cash flow of the business."
• "The launch of our telehealth business and pharmaceutical program are long-term growth drivers that have evolved Niagen from a nutritional supplement business to a multi-asset anti-aging company."
• "For the full year 2026, the Company expects the e-commerce business to grow 10% to 15% year-over-year."
• "We expect Niagen Plus growth and new skincare partnerships to become meaningful contributors beginning in 2027."
• "The Company believes 2026 is an important year of strategic investment and expects operating expenses to increase as it invests across commercial, research and administrative functions to support these strategic priorities, while continuing to focus on disciplined capital allocation and positive cash flow from operations."

Industry Context

StockSavvy.ai notes that Niagen Bioscience is positioning itself beyond its core supplement business into higher-growth, higher-margin areas like telehealth and pharmaceuticals, mirroring a trend seen in some life sciences companies seeking to leverage existing platforms for broader health applications. The focus on NAD+ precursors places it in a growing market segment related to healthy aging and cellular health.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through strategic investments in new growth areas, balanced by increased operating expenses in the near term. Stock repurchases may benefit shareholders.
• Employees: Increased investment in R&D and commercial functions may lead to expanded opportunities. Management's focus on cash flow and disciplined capital allocation aims for sustainable operations.
• Customers: Continued availability of Tru Niagen with strong DTC growth. Expansion of Niagen Plus offers new telehealth and at-home treatment options.
• Partners: Ingredient partners face a more competitive market, potentially impacting sales. New partnerships in skincare are anticipated for 2027.

Next Steps

• Begin preclinical and IND enabling studies for NB4168 in Q3 2026.
• Continue to invest in commercial, research, and administrative functions to support strategic priorities.
• Focus on disciplined capital allocation and positive cash flow from operations.
• Add additional ingredient partners in the near term.
• Achieve meaningful contributions from Niagen Plus and new skincare partnerships beginning in 2027.

Key Dates

Recommendation

The company is making strategic investments for future growth, which is positive, but these investments are increasing operating expenses and impacting near-term profitability. While the core business shows resilience and new ventures like NB4168 are promising, the full impact of these initiatives is not yet realized, warranting a hold position until clearer revenue contributions emerge.

Keywords

Niagen Bioscience, NAD+, Nicotinamide Riboside, Tru Niagen, NB4168, Rare Genetic Diseases, Aging Disorders, Telehealth